The small island state of Bahrain has the third-highest rate of vaccinations per capita in the world so far, according to the Our World in Data website, which is run by an Oxford University research programme

Speaking at the 25th Wharton India Economic Forum, he said the Indian pharma industry ensured the continuity of supplies

Norway COVID-19 immunisation: The Norwegian Institute of Public Health has cautioned against vaccinating elderly people above 80 years of age saying those with a short life span may not benefit much from the jab

Pfizer must conduct local study for vaccine approval: VK Paul Any vaccine maker, including Pfizer, which has sought emergency-use authorisation for its Covid-19 shot in India, must conduct a local \"bridging\" safety and immunogenicity study to be considered for the country's immunisation programme, a senior government official told Reuters. Serum Institute of India, the local manufacturer of the vaccine developed by AstraZeneca and Oxford University, has done a similar study on more than 1...

Around 3 lakh frontline healthcare workers will be inoculated at 2,934 sites across the country on the first day of January 16, according to Health Ministry

As of now, the pre-condition for any vaccine to be implemented in India is that you have to do a bridging trial, said Niti Aayog member VK Paul who also heads National Expert Group On Vaccine Administration for COVID-19 (NEGVAC)

Among these vaccines are those developed by Zydus Cadila, Biological E and Gennova, along with Russia's Sputnik-V vaccine

Pfizer is yet to submit additional data sought by India authorities regarding its COVID-19 vaccine for granting emergency use approval to it; the company has missed last three SEC meetings too

Full authorisation-better known as \"full pre-qualification\"-is a pre-requisite to sell the vaccine in the open market or for mass immunisation of healthy individuals who are not frontline workers

A major incident is defined as one in which there is a risk to life and welfare and is \"beyond the scope of business-as-usual operations. It allows coordination between different emergency agencies and will let London ask for help from other areas

The UK government has already approved COVID-19 vaccine developed by the University of Oxford and AstraZeneca as well as Pfizer-BioNTech for emergency use in the country

US, UK warn Moderna, Pfizer vaccine may cause fever, weak immunity Debates continue in India whether the two COVID-19 vaccines that got emergency use authorisation from the country's drug regulator recently are safe and efficacious. The fact sheets for vaccine recipients in US and UK for Moderna and Pfizer-BioNTech vaccines say the vaccines are yet to be fully approved. Moderna's fact sheet for recipients says its vaccine is unapproved and 'may prevent COVID-19'. The UK government says it h...

Fact sheets for recipients of Moderna and Pfizer-BioNTech vaccines in US and UK clarify that the vaccines are yet to be fully approved; recipients have been asked to get help if they experience severe side effects or allergic reactions

(For) all our vaccines, we are looking at right now..(we) are targeting 2-8 degree because our logistics are worked out on that basis and we are working on that, DBT secretary Renu Swarup said at a press briefing

There was immense pressure on governments to develop a vaccine at the earliest due to the destruction COVID-19 pandemic was unleashing. This led to a race among pharma companies to be the first to develop a vaccine

Without naming Serum Institute CEO Adar Poonawalla, who had termed vaccines other than that of Pfizer, Moderna and Oxford-AstraZeneca as 'just like water', Krishna Ella said, 'We do 200 per cent honest clinical trials and yet we receive backlash'

Bharat Biotech's Chairman and Managing Director Dr. Krishna Ella, in a press conference on Monday, January 5, clarified that its vaccine is safe and the company is conducting trials in over 12 countries besides India

Defending Covaxin, the Bhart Biotech Chairman said that his company has tremendous experience in developing vaccines; more than 70 articles on data related to Covaxin have been published in various journals

COVID-19 vaccine: The ministry added that the doctor has a history of allergic reactions and said that there is no evidence from clinical trials that anyone has developed an inflammation of the brain after the vaccine's application

While AstraZeneca says it expects 2 million doses of the Oxford University vaccine to be ready each week in just over a fortnight, Pfizer BioNTech said the number of doses it has now sent to the UK is 'in the millions'